Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (NCT06577376) | Shanghai Runshi Pharmaceutical Technology Co., Ltd | 2024-08-26 |
Track Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past automatically
Every clearance here is in the API, with alerts when new ones post.